Future directions in sickle cell disease.
作者信息
Anand A
出版信息
West J Med. 1993 May;158(5):536-7.
Abstract
摘要
相似文献
1
Future directions in sickle cell disease.镰状细胞病的未来发展方向。
West J Med. 1993 May;158(5):536-7.
2
Sickle cell patients find a brand New World.镰状细胞病患者迎来了全新的世界。
N J Med. 1999 Aug;96(8):23-5.
3
Hydroxyurea and new agents for the treatment of sickle cell disease.羟基脲及治疗镰状细胞病的新型药物
Clin Adv Hematol Oncol. 2004 Nov;2(11):713-5.
4
Understanding antisickling agents and the sickling process.了解抗镰状化剂和镰状化过程。
Nurs Clin North Am. 1983 Mar;18(1):207-14.
5
Hydroxyurea for sickle cell anemia.羟基脲用于镰状细胞贫血。
N Engl J Med. 2008 Jul 3;359(1):98; author reply 98-9.
6
[Edifying affair of hydroxycarbamid].[羟基脲的启迪之事]
Rev Med Suisse. 2008 Apr 9;4(152):940.
7
Hydroxyurea in very young children with sickle cell anemia is not a cure-all.羟基脲对镰状细胞贫血的幼儿并非万灵药。
J Pediatr. 2001 Dec;139(6):763-4. doi: 10.1067/mpd.2001.120093.
8
Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment.镰状细胞病患者在羟基脲治疗期间循环内皮素-3水平
Haematologica. 2004 Mar;89(3):360-1.
9
Hydroxyurea therapy: improving the lives of patients with sickle cell disease.羟基脲疗法：改善镰状细胞病患者的生活
Pediatr Nurs. 2006 Nov-Dec;32(6):541-3.
10
Established and experimental treatments for sickle cell disease.镰状细胞病的既定治疗方法和实验性治疗方法。
Haematologica. 2004 Mar;89(3):348-56.
本文引用的文献
1
2
A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis.枸橼酸西替地尔用于镰状细胞危象的双盲随机合作研究。
Blood. 1986 May;67(5):1442-7.
3
Is there a role for selective vasodilation in the management of sickle cell disease?
Blood. 1988 Mar;71(3):597-602.
4
Double-blind randomised clinical trial of pentoxiphyllin in vaso-occlusive sickle cell crisis.
Trop Geogr Med. 1989 Oct;41(4):320-5.
5
Future prospects for treatment of hemoglobinopathies.血红蛋白病的未来治疗前景。
West J Med. 1992 Dec;157(6):631-6.
Zotero 插件